TAK - Takeda Pharmaceutical Company Limited

NYSE - NYSE Delayed Price. Currency in USD
17.63
+0.38 (+2.20%)
At close: 4:02PM EDT

17.59 -0.04 (-0.25%)
After hours: 4:26PM EDT

Stock chart is not supported by your current browser
Previous Close17.25
Open17.36
Bid17.62 x 900
Ask17.63 x 2200
Day's Range17.36 - 17.64
52 Week Range15.50 - 21.61
Volume1,825,043
Avg. Volume1,398,726
Market Cap55.288B
Beta (3Y Monthly)0.95
PE Ratio (TTM)21.73
EPS (TTM)0.81
Earnings DateN/A
Forward Dividend & Yield0.83 (4.84%)
Ex-Dividend Date2019-03-28
1y Target Est23.76
Trade prices are not sourced from all markets
  • Benzinga

    The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...

  • Reuters

    UPDATE 1-Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino

    Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million. The sale, which Takeda said in a statement is expected to close in the quarter ending March, comes as Japan's biggest drugmaker looks to trim its debt following the $59 billion purchase of Shire.

  • Business Wire

    Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa (NEMEA) countries within its Growth and Emerging Markets Business Unit to Acino for a total value in excess of $200 million USD. “The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimize our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target leverage ratio,” said Costa Saroukos, Chief Financial Officer, Takeda.

  • Easy Investing Secrets to an Early Retirement - October 11, 2019
    Zacks

    Easy Investing Secrets to an Early Retirement - October 11, 2019

    Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

  • Takeda Nears Russia, Mideast Asset Sale to Private Equity
    Bloomberg

    Takeda Nears Russia, Mideast Asset Sale to Private Equity

    (Bloomberg) -- Takeda Pharmaceutical Co. is nearing the sale of a portfolio of assets in the Middle East, Africa and Russia to separate buyout firms that could help the drugmaker raise about $1 billion to reduce debt, according to people familiar with the matter.The Japanese company is in advanced talks to sell over-the-counter and prescription-drug assets in Russia to Stada Arzneimittel AG, the German pharmaceutical firm owned by Cinven and Bain Capital, the people said, asking not to be identified because the deliberations are private.It’s also close to reaching an agreement to sell its assets in the Middle East and Africa to Acino International AG, a Swiss company owned by Nordic Capital and Avista Capital Partners, they said.No final decision has been made and talks could still fall apart or face delays, the people said. Representatives for Takeda, Stada, Cinven, Bain, Nordic Capital and Avista declined to comment.Shares of Takeda rose 0.9% to close at 3,720 yen Friday in Tokyo.Takeda is also seeking to sell other over-the-counter and prescription-drug businesses in Latin America, Asia and western Europe, Bloomberg News reported last month.The drugmaker is aiming to raise about $10 billion of disposals, simplifying its portfolio and cutting debt after its $62 billion takeover of Shire Plc. The company is looking to divest non-core businesses outside Japan where the company isn’t an industry leader and doesn’t have critical mass in the market.In May, Takeda agreed to sell eye-disease medicines to Novartis AG for as much as $5.3 billion.(Updates with background on previous disposal in last paragraph)\--With assistance from Michael Hytha.To contact the reporters on this story: Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.net;Sarah Syed in London at ssyed35@bloomberg.netTo contact the editors responsible for this story: Fion Li at fli59@bloomberg.net, ;Dinesh Nair at dnair5@bloomberg.net, Amy Thomson, Aaron KirchfeldFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Should You Avoid Takeda Pharmaceutical Company Limited (TAK)?
    Insider Monkey

    Should You Avoid Takeda Pharmaceutical Company Limited (TAK)?

    Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]

  • Signs That Your Trading Will Ruin Your Retirement - October 09, 2019
    Zacks

    Signs That Your Trading Will Ruin Your Retirement - October 09, 2019

    From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

  • Here Is Hedge Funds’ 22nd Most Popular Stock Pick
    Insider Monkey

    Here Is Hedge Funds’ 22nd Most Popular Stock Pick

    Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]

  • Benzinga

    Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar

    Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value protein-based therapeutics and vaccines. The most advanced product candidate in Pfenex' pipeline, PF708, is inching closer to commercialization.

  • As Buyout Fever Grows, Alexion, Amarion and BioMarin Are Potential Targets
    GuruFocus.com

    As Buyout Fever Grows, Alexion, Amarion and BioMarin Are Potential Targets

    The pace of acquisitions in the biotech industry is expected to accelerate as big pharma seeks to boost growth Continue reading...

  • Takeda Is Close to Selling Emerging Market, European Drugs
    Bloomberg

    Takeda Is Close to Selling Emerging Market, European Drugs

    (Bloomberg) -- Takeda Pharmaceutical Co. is close to selling some assets in emerging markets and western Europe, people familiar with the matter said, a move that would help the Japanese drugmaker reduce its debt pile.Takeda may announce a sale of over-the-counter and prescription drugs in Latin America, the Middle East, Africa, Russia and Asia as early as in the coming weeks, the people said, asking not to be identified because the matter is private. A sale of the drugs, which Takeda acquired through its 2011 purchase of Swiss rival Nycomed, could fetch about $3 billion in total, Bloomberg News first reported in January.The company may decide to sell the products to different buyers by geography, the people said. Acino International AG, backed by buyout firms Nordic Capital and Avista Capital Partners, and Stada Arzneimittel AG, owned by Cinven and Bain Capital, are among bidders for different assets, the people said. Other companies that have shown an interest in some of the assets include Brazil’s EMS SA and Uniao Quimica Farmaceutica Nacional SA, the people said.A separate sale by Takeda of OTC and prescription medicines in Western Europe has drawn interest from private-equity firms such as Advent International, which owns drugmaker Zentiva, as well as Apollo Global Management Inc. and Cerberus Capital Management, the people said. The assets could be valued at about 1 billion euros ($1.1 billion), people familiar with the matter said in October.The asset sales would help Takeda reduce debt and simplify its portfolio after its $62 billion takeover of Shire Plc. The Tokyo-based company wants to offload all assets not core to its focus on gastroenterology, oncology, neuroscience, rare diseases and plasma-derived therapies, and has set a target of $10 billion worth of divestment altogether.In May, Takeda agreed to sell eye-disease medicines to Novartis AG for as much as $5.3 billion. The drugmaker said in July that it is confident it can cut its debt to two times earnings before interest, tax, depreciation and amortization in three to five years.Deliberations are ongoing, and other bidders could still emerge, the people said. Representatives for Takeda, Advent, Apollo, Cerberus, Stada, Acino, EMS and Uniao Quimica declined to comment. (Updates with Uniao Quimica interest in third paragraph.)\--With assistance from Tim Loh, Sarah Syed, Fabiola Moura, Kati Pohjanpalo, Lisa Du and Rachel Chang.To contact the reporters on this story: Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net;Cristiane Lucchesi in Sao Paulo at clucchesi5@bloomberg.netTo contact the editors responsible for this story: Fion Li at fli59@bloomberg.net, Ville Heiskanen, Ben ScentFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Benzinga

    The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The ...

  • Business Wire

    New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1

    − Early proof of concept study showed TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo

  • Business Wire

    First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab

    Takeda Pharmaceutical Company Limited today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective

  • Business Wire

    New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda’s TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection

    – From the results of a Phase 2 study, maribavir, an investigational agent that targets a specific CMV protein, may result in the clearance of CMV infections, a condition with pote

  • GuruFocus.com

    Investors May Want to Follow the Progress of These Biotechs

    Companies recognized by key industry publication for innovative approaches Continue reading...

  • Business Wire

    Takeda Recognized in the 2019 Dow Jones Sustainability World Index

    OSAKA, Japan-- -- Also named in Dow Jones Sustainability Asia Pacific Index for 10th Consecutive Year Achieved more than double the average pharmaceutical industry sustainability score Demonstrated significant year-over-year growth in score for strategy to improve access to medicines   Takeda Pharmaceutical Company Limited today announced that it has been named in the 2019 Dow Jones Sustainability ...

  • NICE Recommends Takhzyro®▼(Lanadelumab) for the Treatment of People Living with Rare Debilitating Genetic Disorder
    PR Newswire

    NICE Recommends Takhzyro®▼(Lanadelumab) for the Treatment of People Living with Rare Debilitating Genetic Disorder

    −  Takeda UK Ltd. is pleased to announce that NICE has recommended the use of   Takhzyro® ▼ (lanadelumab)  subcutaneous injection as an option for preventing  recurrent attacks of hereditary angioedema ...

  • Karyopharm Signs $150M Royalty Agreement to Support Xpovio
    Zacks

    Karyopharm Signs $150M Royalty Agreement to Support Xpovio

    Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.

  • Benzinga

    The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure ...

  • Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate
    PR Newswire

    Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

    OSAKA, Japan, Sept. 6, 2019 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). This recall is being conducted after discussions with the FDA and is effective immediately due to a potential issue related to rubber particulates originating from the rubber septum of the NATPARA cartridge. During the 14-day NATPARA treatment period, the septum is punctured by a needle each day to obtain the daily dosage of NATPARA solution.